Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer

被引:62
|
作者
McPhillips, F
Mullen, P
Monia, BP
Dorr, FA
Smyth, JF
Langdon, SP [1 ]
机构
[1] Western Gen Hosp, Imperial Canc Res Fund, Med Oncol Unit, Edinburgh EH4 2XU, Midlothian, Scotland
[2] ISIS Pharmaceut Inc, Carlsbad, CA USA
关键词
Raf; antisense; ovarian; cancer; oligodeoxynucleotide;
D O I
10.1054/bjoc.2001.2139
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
c-Raf is an essential component of the extracellular related kinase (ERK) signal transduction pathway. Immunohistochemical staining indicated that c-Raf was present in 49/53 ovarian adenocarcinomas investigated and high c-Raf expression correlated significantly with poor survival (P = 0.002). c-Raf protein was detected in 15 ovarian cancer cell lines. Antisense oligodeoxynucleotides (ODNs) (ISIS 5132 and ISIS 13650) reduced c-Raf protein levels and inhibited cell proliferation in vitro. Selectivity was demonstrated by the lack of effect of ISIS 5132 on A-Raf or ERK, while a random ODN produced only minor effects on growth and did not influence c-Raf expression. ISIS 5132 produced enhanced apoptosis and cells accumulated in S and G)M phases of the cell cycle. In vivo, ISIS 5132 inhibited growth of the s.c. SKOV-3 xenograft while a mismatch ODN had no effect. These data indicate that high levels of c-Raf expression may be important in ovarian cancer and use of antisense ODNs targeted to c-Raf could provide a strategy for the treatment of this disease. (C) 2001 Cancer Research Campaign.
引用
收藏
页码:1753 / 1758
页数:6
相关论文
共 50 条
  • [31] The association of VEGF A, B, and C expression in the survival of serous ovarian cancer patients
    Chan, J.
    Kiet, T.
    Sherman, A.
    Monk, B.
    Kapp, D.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S131 - S132
  • [32] Anti-tumor activity of C-raf antisense (vol 2, pg 668, 1996)
    Monia, BP
    NATURE MEDICINE, 1999, 5 (02) : 127 - 127
  • [33] C-RAF SENSITIVITY OF RAS-RESPONSIVE GENE-EXPRESSION
    JOHNSTON, JF
    LEBRUN, S
    DEAN, NM
    BENNETT, CF
    MONIA, BP
    FASEB JOURNAL, 1992, 6 (05): : A1644 - A1644
  • [34] Antisense Oligonucleotides Targeting Raf-1 Block Japanese Encephalitis Virus In Vitro and In Vivo
    Zhang, Li
    Li, Qingjun
    Ding, Xiaoran
    Zhang, Bo
    Zhang, Qiling
    Qu, Xinyan
    Huo, Yujia
    Yang, Jing
    Wang, Shengqi
    NUCLEIC ACID THERAPEUTICS, 2017, 27 (02) : 78 - 86
  • [35] Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics
    Le, Bao T.
    Raguraman, Prithi
    Kosbar, Tamer R.
    Fletcher, Susan
    Wilton, Steve D.
    Veedu, Rakesh N.
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2019, 14 : 142 - 157
  • [36] XENOPUS C-RAF PROTOONCOGENE - CLONING AND EXPRESSION DURING OOGENESIS AND EARLY DEVELOPMENT
    LEGUELLEC, R
    COUTURIER, A
    LEGUELLEC, K
    PARIS, J
    LEFUR, N
    PHILIPPE, M
    BIOLOGY OF THE CELL, 1991, 72 (1-2) : 39 - 45
  • [37] c-Raf regulates cell survival and retinal ganglion cell morphogenesis during neurogenesis
    Pimentel, B
    Sanz, C
    Varela-Nieto, I
    Rapp, UR
    De Pablo, F
    de la Rosa, EJ
    JOURNAL OF NEUROSCIENCE, 2000, 20 (09): : 3254 - 3262
  • [38] Control of cyclin D1 expression by antisense oligonucleotides in three ovarian cancer cell lines
    Cagnoli, M
    Barbieri, F
    Bruzzo, C
    Alama, A
    GYNECOLOGIC ONCOLOGY, 1998, 70 (03) : 372 - 377
  • [39] A phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer
    Cunningham, CC
    Holmlund, JT
    Schiller, JH
    Geary, RS
    Kwoh, TJ
    Dorr, A
    Nemunaitis, J
    CLINICAL CANCER RESEARCH, 2000, 6 (05) : 1626 - 1631
  • [40] ROS and mitochondrial Ca2+ are critical targets for survival signaling by C-Raf
    Kuznetsov, A. V.
    Doblander, C.
    Hermann, M.
    Janakiraman, M.
    Sucher, R.
    Smigelskaite, J.
    Troppmair, J.
    BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS, 2006, : 426 - 426